S&P 500   4,309.91 (+0.30%)
DOW   34,179.24 (+0.79%)
QQQ   332.28 (-0.23%)
AAPL   172.88 (-0.18%)
MSFT   292.73 (-0.25%)
META   179.26 (-0.90%)
GOOGL   121.86 (-0.18%)
AMZN   143.91 (+0.51%)
TSLA   927.65 (-0.03%)
NVDA   188.48 (-0.97%)
NIO   20.80 (-2.35%)
BABA   92.73 (-1.56%)
AMD   99.71 (-1.29%)
MU   64.04 (-1.02%)
T   18.63 (+1.31%)
CGC   3.65 (-4.45%)
F   16.42 (+0.61%)
GE   80.24 (+0.54%)
DIS   125.14 (+0.71%)
AMC   24.23 (+0.08%)
PYPL   102.29 (+0.77%)
PFE   49.62 (-0.26%)
NFLX   247.21 (-0.76%)
S&P 500   4,309.91 (+0.30%)
DOW   34,179.24 (+0.79%)
QQQ   332.28 (-0.23%)
AAPL   172.88 (-0.18%)
MSFT   292.73 (-0.25%)
META   179.26 (-0.90%)
GOOGL   121.86 (-0.18%)
AMZN   143.91 (+0.51%)
TSLA   927.65 (-0.03%)
NVDA   188.48 (-0.97%)
NIO   20.80 (-2.35%)
BABA   92.73 (-1.56%)
AMD   99.71 (-1.29%)
MU   64.04 (-1.02%)
T   18.63 (+1.31%)
CGC   3.65 (-4.45%)
F   16.42 (+0.61%)
GE   80.24 (+0.54%)
DIS   125.14 (+0.71%)
AMC   24.23 (+0.08%)
PYPL   102.29 (+0.77%)
PFE   49.62 (-0.26%)
NFLX   247.21 (-0.76%)
S&P 500   4,309.91 (+0.30%)
DOW   34,179.24 (+0.79%)
QQQ   332.28 (-0.23%)
AAPL   172.88 (-0.18%)
MSFT   292.73 (-0.25%)
META   179.26 (-0.90%)
GOOGL   121.86 (-0.18%)
AMZN   143.91 (+0.51%)
TSLA   927.65 (-0.03%)
NVDA   188.48 (-0.97%)
NIO   20.80 (-2.35%)
BABA   92.73 (-1.56%)
AMD   99.71 (-1.29%)
MU   64.04 (-1.02%)
T   18.63 (+1.31%)
CGC   3.65 (-4.45%)
F   16.42 (+0.61%)
GE   80.24 (+0.54%)
DIS   125.14 (+0.71%)
AMC   24.23 (+0.08%)
PYPL   102.29 (+0.77%)
PFE   49.62 (-0.26%)
NFLX   247.21 (-0.76%)
S&P 500   4,309.91 (+0.30%)
DOW   34,179.24 (+0.79%)
QQQ   332.28 (-0.23%)
AAPL   172.88 (-0.18%)
MSFT   292.73 (-0.25%)
META   179.26 (-0.90%)
GOOGL   121.86 (-0.18%)
AMZN   143.91 (+0.51%)
TSLA   927.65 (-0.03%)
NVDA   188.48 (-0.97%)
NIO   20.80 (-2.35%)
BABA   92.73 (-1.56%)
AMD   99.71 (-1.29%)
MU   64.04 (-1.02%)
T   18.63 (+1.31%)
CGC   3.65 (-4.45%)
F   16.42 (+0.61%)
GE   80.24 (+0.54%)
DIS   125.14 (+0.71%)
AMC   24.23 (+0.08%)
PYPL   102.29 (+0.77%)
PFE   49.62 (-0.26%)
NFLX   247.21 (-0.76%)
NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$380.98
-9.87 (-2.53%)
(As of 08/16/2022 11:44 AM ET)
Add
Compare
Today's Range
$371.10
$385.73
50-Day Range
$327.37
$407.78
52-Week Range
$318.50
$695.18
Volume
6,882 shs
Average Volume
580,368 shs
Market Capitalization
$31.72 billion
P/E Ratio
49.16
Dividend Yield
N/A
Price Target
$483.57

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
29.0% Upside
$483.57 Price Target
Short Interest
Healthy
2.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.68
Upright™ Environmental Score
News Sentiment
0.21mentions of IDEXX Laboratories in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
21.49%
From $7.91 to $9.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.11 out of 5 stars

Medical Sector

63rd out of 1,124 stocks

Diagnostic Substances Industry

1st out of 18 stocks

IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IDXX shares. Barclays dropped their price objective on shares of IDEXX Laboratories from $700.00 to $582.00 and set an "overweight" rating on the stock in a report on Friday, August 5th. The Goldman Sachs Group upgraded shares of IDEXX Laboratories from a "neutral" rating to a "buy" rating and cut their price target for the company from $530.00 to $435.00 in a report on Thursday, July 21st. Atlantic Securities reduced their price objective on IDEXX Laboratories from $500.00 to $490.00 and set an "overweight" rating for the company in a research note on Wednesday, August 3rd. Stifel Nicolaus cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating and set a $415.00 target price for the company. in a research report on Wednesday, August 3rd. Finally, StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, July 25th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $483.57.

IDEXX Laboratories Trading Down 1.4 %

NASDAQ:IDXX traded down $5.52 during mid-day trading on Monday, reaching $390.91. The company's stock had a trading volume of 10,944 shares, compared to its average volume of 609,693. The stock has a market cap of $32.54 billion, a P/E ratio of 51.15, a P/E/G ratio of 5.28 and a beta of 1.14. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.89 and a quick ratio of 0.61. The company's fifty day simple moving average is $370.31 and its two-hundred day simple moving average is $439.45. IDEXX Laboratories has a twelve month low of $318.50 and a twelve month high of $695.18.

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

IDEXX Laboratories Stock Is Very Expensive
IDEXX Laboratories (NASDAQ:IDXX) Price Target Cut to $420.00
Stifel Nicolaus Lowers IDEXX Laboratories (NASDAQ:IDXX) to Hold
IDEXX Laboratories (NASDAQ:IDXX) Price Target Cut to $490.00
IDEXX Laboratories Slashes FY22 Outlook - Update
IDEXX Laboratories (NASDAQ:IDXX) PT Lowered to $420.00
IDEXX Laboratories (NASDAQ:IDXX) Shares Gap Down to $393.51
StockNews.com Lowers IDEXX Laboratories (NASDAQ:IDXX) to Hold
Nasdaq 100 Movers: IDXX, ISRG
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings
11/02/2021
Today
8/16/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,350
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$483.57
High Stock Price Forecast
$582.00
Low Stock Price Forecast
$415.00
Forecasted Upside/Downside
+26.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$744.84 million
Pretax Margin
24.89%

Debt

Sales & Book Value

Annual Sales
$3.22 billion
Cash Flow
$9.63 per share
Book Value
$8.14 per share

Miscellaneous

Free Float
81,539,000
Market Cap
$31.72 billion
Optionable
Optionable
Beta
1.14

Social Links















IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2022?

8 Wall Street research analysts have issued 12-month price targets for IDEXX Laboratories' stock. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they expect the company's stock price to reach $483.57 in the next year. This suggests a possible upside of 23.7% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2022?

IDEXX Laboratories' stock was trading at $658.46 at the beginning of the year. Since then, IDXX stock has decreased by 40.6% and is now trading at $390.85.
View the best growth stocks for 2022 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.15. The business had revenue of $810.42 million for the quarter, compared to analysts' expectations of $793.26 million. IDEXX Laboratories had a trailing twelve-month return on equity of 104.47% and a net margin of 20.07%. During the same period in the prior year, the business earned $1.69 EPS.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of $7.77-$8.05 for the period, compared to the consensus estimate of $8.27. The company issued revenue guidance of $3.31 billion-$3.38 billion, compared to the consensus revenue estimate of $3.42 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (4.39%), FMR LLC (2.48%), Franklin Resources Inc. (1.46%), Brown Advisory Inc. (1.34%), Northern Trust Corp (1.08%) and Principal Financial Group Inc. (0.71%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $390.85.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $32.54 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.75 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 10,350 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.